Giuliana Grossi

Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options expanding treatment choice.

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and CRC mortality.

DOJ policy shifts have put HHS on the same side as states seeking to narrow Section 504's disability integration mandate in Texas v Kennedy.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.

Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy.

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare's GLP-1 bridge program.

Policy makers should vet the methodology behind reported cost savings before trusting the numbers, says Halima Ahmadi-Montecalvo, PhD, MPH.

The FDA has approved oveporexton (Orzeyful), the first orexin agonist for narcolepsy type 1, based on phase 3 data showing broad symptom improvement.

Waist circumference (WC) predicts mortality risk in older adults independent of BMI, with high WC linked to 24% greater death risk, a new study finds.

Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.

ADCs and oral SERDs are reshaping breast cancer care, easing toxicity but adding new sequencing, HER2 testing, and adherence challenges.

Closed-loop referral systems confirm outcomes, not just referrals, avoiding false success and building durable, scalable social care infrastructure.

Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Bridget Keenan, MD, PhD, of UCSF, stresses close communication across clinical, industry, and lab teams to run safe CAR T-cell trials.

CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.

Setmelanotide cut BMI 16.5% in a trial for acquired hypothalamic obesity, easing hyperphagia, though adverse events require close monitoring.

Bipartisan Senate bill would codify 340B patient rules, end rebate model, boost oversight—as CMS separately proposes deep Medicare 340B payment cuts.

New smartwatch data show women's nighttime awakenings jump sharply at midlife—far more than men's—hinting at a menopause-linked sleep shift.

Lilly opens early access to retatrutide for some patients before FDA approval, following scrutiny over a single earlier compassionate-use case.

UPMC and Birth Root Community Doula describe a 4-year partnership addressing food insecurity, housing, and maternal health disparities.

GPBCH's podcast series helps employers navigate GLP-1 strategy and oncology care access, pairing data-driven insights with patient literacy tools.

At an AJMC roundtable, Boston clinicians detailed fragmented obesity care access, prior authorization burdens, and looming GLP-1 coverage shifts.

Black, Latino boys' stigma persists; AHRQ halts 100+ grants; Delgocitinib succeeds in teens; Medicaid frail rule stands; BIPOC eating care improves.

Researchers say the Trump administration has quietly shut down most Agency for Healthcare Research and Quality grantmaking, halting 100+ safety studies.

In a small, placebo-controlled trial, oral semaglutide reduced heavy drinking days and craving in adults with AUD, though it missed its primary end point.

The FDA's push for faster, more diverse trials misses the real fix: experts say AI simulation and readability, not red tape, close the gap.

This eta-analysis shows sleep variability—not averages—signals psychosis risk, with stage-specific patterns to guide digital biomarkers and care.